ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Activin RIB

Activin RIB

概要

Name:Transforming growth factor beta receptor 1
Target Synonym:EC 2.7.11,TGF-beta type I receptor,Serine/threonine-protein kinase receptor R4,TGFBR1,Activin A receptor type II-like protein kinase of 53kD,Transforming Growth Factor Beta Receptor 1,Transforming Growth Factor-Beta Receptor Type I,Activin A Receptor Type II-Like Kinase, 53kDa,Activin Receptor-Like Kinase 5,TGFR-1,ALK-5,ALK5,SKR4,Mutant Transforming Growth Factor Beta Receptor I,TGF-Beta Receptor Type-1,TGF-Beta Receptor Type I,EC 2.7.11.30,ACVRLK4,LDS1A,LDS2A,AAT5,LDS1,TBRI,ESS1,MSSE,TbetaR-I,T
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
ACB-H52H4 Human Human Activin RIB / ACVR1B Protein, His Tag
ACB-H52H4-structure
ACB-H52H4-sds
ACRO Quality

生物活性データの一部

ACB-H52H4-SPR
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human TDGF1, Fc Tag on Protein A Biosensor, can bind Human Activin RIB, His Tag (Cat. No. ACB-H52H4) with an affinity constant of 5.6 μM as determined in BLI assay (ForteBio Octet Red96e) (QC Tested).

Synonym Name

ACVR1b,ALK4,ACVRLK4,ACTR-IB,SKR2

Background

Activin receptor type-1B (ACVR1B) is also known as Activin receptor-like kinase 4 (ALK-4), Serine/threonine-protein kinase receptor R2 (SKR2), which belongs to the protein kinase superfamily, TKL Ser/Thr protein kinase family and TGFB receptor subfamily. ACVR1B contains one GS domain and one protein kinase domain. The catalytic activity of ACVR1B is “ATP + [receptor-protein] = ADP + [receptor-protein] phosphate”. ACVR1B acts as a transducer of activin or activin like ligands (e.g., inhibin) signals. Activin binds to either ACVR2A or ACVR2B and then forms a complex with ACVR1B. These go on to recruit the R-SMADs SMAD2 or SMAD3. ACVR1B also transduces signals of nodal, GDF-1, and Vg1.

Clinical and Translational Updates

相関分子

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Galunisertib LY-2157299 Phase 2 Clinical Eli Lilly And Company Breast Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Solid tumours; Neoplasms; Myelodysplastic Syndromes; Glioblastoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Liver Neoplasms Details
GF-101 GFH-018; GF-101; GFH018 Phase 2 Clinical Genfleet Therapeutics (Shanghai) Inc Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
ORG-129 ORG-129; AGMB-129 Phase 2 Clinical Origo Biopharma Sociedad Litmitada Crohn Disease Details
TRK-250 TRK-250; BNC-1021 Phase 1 Clinical Bonac Corp Idiopathic Pulmonary Fibrosis Details
Itacnosertib TP-0184 Phase 1 Clinical Tolero Pharmaceuticals Inc, Sumitomo Dainippon Solid tumours; Anemia Details
Oxinseti SH-3051 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Solid tumours; Liver Neoplasms Details
AGMB-447 AGMB-447; ORG-447 Phase 1 Clinical AgomAb Therapeutics NV Idiopathic Pulmonary Fibrosis Details
TD-1058 Phase 1 Clinical Theravance Biopharma Inc Idiopathic Pulmonary Fibrosis Details

This web search service is supported by Google Inc.

totopphone